Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Caike Biotechnology

Explore full profile

Advanced life science tools for high-resolution data

Suzhou Shi, China
Valuation $100–250M Last recorded · 2021
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Caike Biotechnology and the history behind them.

About Caike Biotechnology

Caike (Suzhou) Biotechnology Co., Ltd. is a life sciences company that develops and produces advanced research tools and instruments. Founded in 2018 in the Suzhou BioBay by several PhDs returning from the United States, the firm focuses on providing high-resolution data for life science researchers. The company's core technology, μ-MPF (Micro-scaled Multi-Physics coupled Force), underpins its product line, which includes a high-throughput single-cell photoconductive system and a single-molecule immunoassay analyzer. These products are designed to enhance research at the single-cell and single-molecule levels, enabling highly sensitive detection of biomarkers and functional screening.

Caike Biotechnology's business model is centered on developing and commercializing its proprietary platform technology and associated products, including instruments and reagents, for the life sciences and in-vitro diagnostics markets. The company serves researchers and clinicians, providing tools for applications such as the development and validation of low-abundance biomarkers, bioanalysis in drug development, and early disease detection and prognosis. For example, their single-molecule immunoassay system can directly analyze biomarkers in serum, plasma, and other biological fluids with ultra-high sensitivity.

Since its inception, Caike Biotechnology has achieved significant milestones and secured substantial funding. The company received an angel round investment in 2020 from IDG Capital and Borui Bio-medicine. This was followed in 2021 by Series A-1 and A-2 financing rounds, co-led by IDG Capital, Langyu Capital, and PerkinElmer Ventures, and a 150 million yuan Series B round co-led by Legend Capital, Hillhouse Capital, and CMG-SDIC Capital. In 2022, the company's single-molecule equipment received NMPA approval for IVD use, and its single-cell products were officially launched. The firm has also established a marketing center in Shanghai and an application technology center to support customer-driven R&D.

Source: Dealroom company data

At a glance

Status
Operational
Headquarters
Suzhou Shi, China
Open positions
None listed
Dealroom signal
12.4/100
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Dec 2021 $21M $83M Legend Capital · SDIC China Merchants · IDG Capital · Honghui China ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Caike Biotechnology website traffic

Latest recorded traffic for Caike Biotechnology is 960 monthly website visits, up 39.1% over the last three months.

Latest monthly visits960 3-month web change+39.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Caike Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Caike Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.